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Risk factors for late kidney allograft failure. markable improvement of graft survival in the short-
Background. While graft survival rates in the short term term, large surveys reported only a modest increase in
have improved dramatically, only a modest improvement has the projected graft half-life [1]. Therefore, the attentionbeen shown in long-term graft survival rates. We evaluated the
of the transplant community is now focused on the causescauses of late failure in renal allograft recipients treated with
of late allograft failure and their prevention.cyclosporine A (CsA).
Methods. A total of 864 adults with a functioning graft at In this retrospective analysis of a single-center experi-
one year were evaluated. The end points were dialysis or death ence, we tried to identify the risk factors associated with
with a functioning graft. late failure in renal transplant recipients who were treatedResults. The 13-year patient and graft survival probabilities
with cyclosporine (CsA) and who had their kidney allo-were 0.82 and 0.64, respectively. The graft half-life was 20.1
graft functioning for at least one year.years and the pure graft half-life was 31.1 years. At multivariate
analysis, plasma creatinine at one year (P  0.0006; RR 1.72),
low-density lipoproteins (LDL) at one year (P  0.0014; RR
METHODS1.65), older age (P  0.0128; RR 1.50) and delayed graft func-
tion (P  0.0350; RR 1.45) were associated with the end point. Criteria for inclusion
Chronic allograft nephropathy was the cause of failure in 97
The following inclusion criteria were followed for en-patients, death in 70, recurrence of glomerulonephritis in 24,
other events in 6. Cardiovascular complications were the most rolling patients into the analysis: (a) age more than 15
frequent cause of death. Post-transplant cardiovascular events years at transplantation; (b) first renal transplantation;
were associated with: pre-transplant cardiovascular events (P (c) treatment with CsA since transplantation; (d) an allo-0.0012; RR 2.65), older age (P  0.0001; RR 2.46), pre-trans-
graft functioning for at least one year.plant arterial hypertension (P  0.0249; RR 1.57), smoking
Five patients who received double organ transplants(P  0.0235; RR 1.29), duration of dialysis (P  0.0229; RR
1.28). Mean serum cholesterol, LDL and triglycerides were each and 12 who stopped CsA before the first year were ex-
significantly associated post-transplant cardiovascular events. cluded from this analysis.
Conclusions. The graft half-life was 20 years. Chronic allo-
graft nephropathy was the leading cause of late failure, fol- Definitions
lowed by death. If the data were censored by death, the pro-
For the aims of this study, chronic allograft nephropa-jected pure graft half-life would be 31.1 years. Pre-transplant
selection and preparation of the candidate as well as appro- thy was defined as a progressive decline of graft function
priate life style are recommended to improve life expectancy not related to treatment interruption, recurrence of origi-
and extend graft survival. nal disease, vascular or urological complications. No at-
tempt to differentiate chronic renal toxicity from chronic
rejection was made.
With the modern immunosuppression the risk of early Recurrence of glomerulonephritis was always diag-
graft failure has been considerably reduced. Today, the nosed by transplant biopsy. All patients with diagnosis of
one-year cadaveric allograft survival probability is around recurrence had a histological diagnosis of the original
90% in many transplant units. However, despite the re- disease on their native kidneys. Graft loss was attributed
to recurrence both on clinical grounds (nephrotic protein-
uria, micro- or macroscopic hematuria) and graft biopsyKey words: kidney transplantation, chronic allograft nephropathy,
features showing for any subtype of glomerulonephritismortality in renal transplantation, glomerulonephritis, immunosuppres-
sion, life style post-transplantation. the typical pattern on immunofluorescence and the char-
acteristic glomerular lesions often associated with diffuseReceived for publication January 10, 2002
glomerular sclerosis or with crescents, particularly in prolif-and in revised form April 23, 2002
Accepted for publication June 10, 2002 erative nephritis such as IgA nephritis, Henoch-Scho¨nlein
disease and membranoproliferative glomerulonephritis. 2002 by the International Society of Nephrology
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Table 1. Mean demographic characteristics of
864 patients at transplantation
Age median (min–max) 39.8 years (15–69)
Sex male/female 567/297
Living/cadaver donor 151/713
Duration of dialysis median 28 months (0–270)
Chronic glomerulonephritis 374
Polycystic kidney disease 90
Urological disease 78
Congenital disease 63
Systemic disease 46
Miscellaneous 66
Undetermined 147
Fig. 1. Patient (dashed line) and graft (solid line) survival probabilities
in 864 cyclosporine A (CsA)-treated renal transplant recipients with
their graft functioning at one year.These glomerular lesions were often associated with vas-
cular and tubulointerstitial lesions.
Delayed graft function was defined as the need of one
or more dialysis sessions after transplantation. Pure patient and graft survivals were calculated by
More difficult was the definition of smokers. We in- censoring the data by death. Graft half-life was calcu-
cluded in the same group the ex-smokers and those pa- lated according to the method of Cho and Terasaki [3].
tients who were smoking continuously at least five ciga- The prognostic impact on cardiovascular events has
rettes per day, while non-smokers were considered to be been evaluated considering also the role of lipid metabo-
patients who never smoked or smoked only sporadically. lism variables (serum cholesterol, triglycerides, HDL,
LDL), blood pressure, smoking and hematocrit, recorded
Statistical analysis
at transplantation, after six months, and then yearly. Since
Cumulative probability of graft survival and of recur- the cardiovascular events occurred with a maximal inci-
rence of glomerulonephritis was estimated according to dence in the first three post-transplant years, we followed
Kaplan and Meier [2]. The prognostic relevance of base- a pragmatic approach by fitting three models, trying to
line covariates for univariate and multivariate analyses evaluate the prognostic relevance of the pattern of these
was assessed by means of the stratified Cox models. time-dependent variables at three different times since
The role of prognostic factors has been assessed for the transplantation. For the first model, the variables taken
following variables at transplantation: sex, age (45 vs. into account were those recorded at baseline; the mean
45 years), source of donor, type of dialysis, months on of the values recorded at the sixth month and at one
dialysis (60 vs. 60 months), pre-transplant hyperten- year has been included in the second model and, finally,
sion (need for one or more drugs), smoking (continuing, the mean of the values recorded in the first three years
any amount), body mass index (25 vs.  25 wt/ht2), in a third model.
hepatitis B and C virus (HBV, HCV) status, number of
human lymphocyte antigen (HLA) mismatches, and left
RESULTSventricular hypertrophy. After transplantation the follow-
ing variables have been considered: type of immunosup- Eight hundred sixty-four renal transplant patients,
who received their allografts between February 1983 andpression (CsA alone vs. CsA plus steroids vs. CsA plus
steroids plus azathioprine or mofetil mycophenolate or June 2000, met the criteria for inclusion and were en-
rolled in this study. The demographic characteristics aresirolimus/everolimus), number of acute rejections (within
the first three months), number of high-dose methylpred- given in Table 1. The patient survival probability at 13
years was 0.82, the graft survival probability at 13 yearsnisolone pulses, use of antilymphocyte antibodies, de-
layed graft function, plasma creatinine (1.5 vs. 1.5 was 0.64 (Fig. 1).
mg/dL), hypertension [mean arterial pressure (MAP)
Risk factors for graft failure110 mm Hg vs. either MAP 110 mm Hg under treat-
ment or 110 mm Hg], hematocrit (36 vs. 36%), The mean graft half-life was 20.1 years, 18.7 for cadav-
eric transplants and 31.9 for living transplants. The mostserum cholesterol (250 vs. 250 mg/dL), serum low-
density lipoproteins (LDL;160 vs.160 mg/dL), serum frequent cause of late failure was chronic allograft nephrop-
athy (97 of 197 events, 49.2%), followed by death (70triglycerides (160 vs. 160 mg/dL) at one year. These
thresholds have been chosen according to their clinical events, 35.5%), recurrent glomerulonephritis (24 events,
12%), renal vessel thrombosis (3 cases, 1.5%), graft ma-relevance.
The end points for graft failures were need of regular lignancy (2 cases, 1.0%), and urological complication
(1 case, 0.5%). Univariate analysis showed that plasmadialysis or death with functioning graft.
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Fig. 2. Mean plasma creatinine levels (mg/dL;
) and standard deviation (; ) in patients
with their graft still functioning.
creatinine1.5 mg/dL at one year (P 0.0001), delayed
graft function (P 0.0003), age older than 45 years (P
0.0015), duration of dialysis longer than 60 months (P 
0.0028), and serum LDL more than 160 mg/dL at one
year (P  0.0065) were significantly associated with late
failure.
At multivariate analysis, increased plasma creatinine
(P  0.0006; RR 1.72), elevated LDL (P  0.0014; RR
1.65), older age (P  0.0128; RR 1.50) and delayed graft
function (P 0.0350; RR 1.45) were significantly associ-
ated with late failure.
Chronic allograft nephropathy Fig. 3. Graft survival probability in two different periods (log-rank
P  0.04): () 1989 to 1994 and (solid line) 1983 to 1988.Loss of graft caused by chronic allograft nephropathy
occurred in 97 of 864 patients (11.2%). Graft failure
occurred in mean after 85.0  47.3 months (median 80.8
months; range 12 to 203). complications, in 19 by cancer, in 11 by infections, in 9
The mean reciprocal of plasma creatinine tended to by liver disease and in 7 by miscellaneous causes.
maintain stable until 13 years in patients with their allo- The fatal cardiovascular complications were: myocar-
grafts still functioning (Fig. 2). dial infarction, 17 cases; cerebral hemorrhage, three; car-
To evaluate whether graft survival probabilities changed diac arrest, two; complicated aortic aneurysm, one; pul-
over the years, two different time periods were com- monary edema, one. Death caused by cardiovascular
pared. The ten-year graft survival probability was sig- events occurred in mean 91.4 50.92 months after trans-
nificantly better for patients transplanted between 1989 plantation (median 79.13 months; range 13 to 175).
and 1994 than for patients transplanted before 1983 and Among fatal cancers, four were lymphomas, four carci-
1988 (Fig. 3). nomas of gastrointestinal tract, three lung cancers, two
liver carcinomas, two pancreas carcinomas, two carcino-
Death mas of the native kidneys, one carcinoma of the trans-
Death occurred in 70 patients, in mean 6.2 3.79 years planted kidney, and one Kaposi sarcoma. Death caused
after transplantation, and was the second cause of late by cancer occurred in mean 81.9  55.95 months after
transplantation (median 69.6 months; range 17 to 185).failure. In 24 cases death was caused by cardiovascular
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els fitted in the follow-up (after one and three years
since transplantation), the type of donor remained at a
borderline level or even less, pre-existing cardiovascular
events lost their relevance, and pre-transplant arterial
hypertension with duration of dialysis remained signifi-
cant prognostic factors only until three years after trans-
plantation (Table 2). Finally, elevated serum cholesterol,
or serum LDL cholesterol or serum triglycerides only,
added once at a time to the final model, gained an inde-
pendent prognostic role, giving very similar increases of
Fig. 4. Pure graft survival probability, excluding death.
the relative risk for each 10 unit increase. If these three
variables were jointly considered in a prognostic model,
serum triglycerides remained into the model as an inde-
pendent prognostic factor.Pneumonia (N  2), post-surgical sepsis, in patients
with polycystic kidney disease (2), necrotizing colitis with
Recurrence of glomerulonephritissepsis (1), cholangitis (1), disseminated tuberculosis (1),
AIDS (1), sepsis of unknown origin (1), urinary sepsis Recurrent glomerulonephritis accounted for 24 graft
failures. Failure occurred in a mean 74.8 51.34 monthsand cachexia in a patient with polycystic kidney disease
(1), and intestinal perforation and sepsis (1) were the (median 61.6 months, range 12 to 171). In 12 cases the
cause was IgA nephritis, in four cases it was membrano-causes of death from infection.
Death due to liver failure occurred in four HBV posi- proliferative glomerulonephritis, in three cases membra-
nous nephropathy, in three cases focal and segmentaltive patients, in two HBV and HCV positive patients,
in one HCV positive patient. Two other patients were glomerulosclerosis, and in two the cause was Henoch-
HBV negative while their HCV status was unknown (both Scho¨nlein nephritis.
patients died before 1989). The 13-year graft survival probabilities were the same
The pure graft survival was calculated by censoring in patients transplanted because of a primary glomerulo-
the data for death. The 13-year pure graft survival with- nephritis and in patients transplanted because of other
out death was 0.72 (Fig. 4). The pure graft half-life was diseases (Fig. 5).
31.1 years.
No attempt was made to search for risk factors of
DISCUSSIONdeath caused by tumors or infections, due to the small
In this retrospective single-center analysis, we chosenumber of events.
a hard endpoint, namely the need for regular dialysis or
Risk factors for cardiovascular events death with a functioning allograft. Among a large num-
ber of variables taken into consideration, only elevatedTo analyze the risk factors associated with cardiovas-
plasma creatinine at one year, elevated LDL at one year,cular complications, since the number of fatal cardio-
older age of the recipient, and delayed graft function werevascular complications was too small to allow a sensible
significantly associated with late graft failure at multivar-statistical analysis, we considered both the fatal and non-
iate analysis. On the contrary, no effect of HLA matchingfatal first cardiovascular events that developed after
was observed. This may be accounted for partly by thetransplantation. In a total of 154 cardiovascular events
fact that more than 80% of our patients had two to fourthere were 44 severe cardiac arrhythmias, 38 occlusive
HLA incompatibilities, which precluded the ability toperipheral arteriopathies, 32 cardiac infarctions, 19 an-
judge the impact of an excellent or a very poor compati-gina pectoris, 16 cerebrovascular complications, five con-
bility. On the other hand, the number of patients in thisgestive heart failures, and two aortic aneurysms requir-
study was too small to allow significant differences be-ing surgery.
tween the various grades of mismatch to be found. Re-As shown in Table 2, among the pre-transplant vari-
ports showing a statistically significant impact of HLA onables, the risk of de novo cardiovascular events during
graft outcome were based on national or internationalthe first year after transplantation was significantly asso-
surveys including many thousands of renal allografts [4, 5].ciated with pre-existing cardiovascular events (P 
Previous studies already pointed out that graft func-0.0012; RR 2.65), older age (P  0.0001; RR 2.46), pre-
tion at 12 months is a strong surrogate marker of latetransplant arterial hypertension (P  0.0249; RR 1.57),
graft outcome [6, 7]. Hyperlipidemia is not only a well es-smoking (P 0.0235; RR 1.29), duration of dialysis (P
tablished risk factor for cardiovascular complications,0.0229; RR 1.28), and with the type of donor at a border-
but also can be responsible of graft vascular lesions even-line significance level, while the lipid levels did not show
any significant prognostic role. Then, considering the mod- tually leading to progressive chronic allograft nephropa-
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Table 2. Multivariate analysis of risk factors for cardiovascular events following transplantation
Prognostic models
Model 1a Model 2b Model 3c
RR 95% CI P RR 95% CI P RR 95% CI P
Age at transplantation
45 vs. 45 years 2.46 1.744–3.466 0.0001 2.46 1.662–3.631 0.0001 2.33 1.483–3.673 0.0003
Living vs. cadaveric donor 0.55 0.304–1.012 0.0548 0.2846 0.46 0.197–1.053 0.0659
Smoking yes vs. no 1.29 1.035–1.611 0.0235 1.32 1.018–1.707 0.0360 1.42 1.049–1.921 0.0233
Months on dialysis
60 vs. 60 1.28 1.035–1.587 0.0229 1.42 1.119–1.813 0.0041 0.3456
Cardiovascular disease before
transplant yes vs. no 2.65 1.472–4.787 0.0012 0.1589 0.1834
Pre-transplant hypertension 1.57 1.059–2.328 0.0249 1.63 1.045–2.556 0.0314 0.1088
And
Triglyceridesd 0.4663 1.02 1.002–1.040 0.0318 1.03 1.009–1.048 0.0038
Or
Total cholesterold 0.9404 1.06 1.020–1.091 0.0018 1.06 1.020–1.110 0.0040
Or
LDL cholesterold 0.3077 1.06 1.014–1.103 0.0098 1.08 1.019–1.145 0.0091
a Model 1: For the 1st year post-transplant, considering triglycerides, total cholesterol and LDL cholesterol basal values
b Model 2: For the 2nd and 3rd year post-transplant, triglycerides, total cholesterol and LDL cholesterol (mean of the 6th month and 1st year values)
c Model 3: For follow-up after the 3rd year post-transplant, triglycerides, total cholesterol and LDL cholesterol considered are the mean of 1st, 2nd, and 3rd year
values
d RR per each 10 mg/dL value increase of these variables
Fig. 5. Graft survival probability in 374 renal
transplant recipients with glomerulonephritis as
a primary cause of renal failure () and in 490
patients with other causes of renal failure (-).
thy [8, 9]. There is a general agreement that an older 45%. Clearly, however, it is likely that all of these vari-
ables remaining in the multivariate model can act inage of the recipient may expose the patient to an in-
creased risk of mortality and morbidity. Moreover, the concert to cause late graft failures.
Chronic allograft nephropathy was the most frequentmorbid events that occur more frequently in older pa-
tients may require a reduction of immunosuppressive cause of graft failure in this study as well as in most
other analyses and surveys. However, only 11% of ourtherapy with consequent increased risk of late irrevers-
ible rejection [10]. Whether delayed graft function is patients eventually lost their allograft because of chronic
allograft nephropathy and this occurred in mean after[11, 12] or is not [13, 14] independently associated with an
increased rate of graft function is still under discussion. In 85 months. Consequently, the graft half-life was good,
ranging around 19 years for cadaveric transplant recipi-this study delayed graft function emerged as an indepen-
dent variable that increased the risk of late failure by ents. For many years the data of the United Network for
Ponticelli et al: Late renal transplant failure 1853
Organ Sharing (UNOS) showed that, despite a dramatic cular events. As cardiovascular disease may develop ap-
proximately 20 years earlier in renal transplant recipi-reduction in the incidence of acute rejection after the
introduction of CsA, the cadaveric graft half-life re- ents than in general population [24], preventive measures
such as aggressive treatment of hyperlipidemia, hyperten-mained fairly stable, ranging around seven to eight years
[15]. However, more recently the same source [1] and sion and diabetes are strongly recommended. Moreover,
any effort should be done to convince the patients to avoidanother large American survey [16] reported a progres-
sive improvement of graft half-life in renal transplant cigarette smoking, physical inactivity and excess weight.
Tumors were the second cause of death in this series.recipients. These data are confirmed by our experience,
as the long-term graft survival was significantly better in It is well known that transplant recipients are exposed
to an increased risk of malignancy [25]. De novo malig-patients transplanted between 1989 and 1994 than in
patients transplanted between 1983 and 1988. Several nancy is now emerging as a major cause of morbidity
and late failure in renal transplantation [26]. Apart fromreasons may account for the improved results in the more
recent period. These include better general medical care, age and genetic predisposition, the intensity and the du-
ration of immunosuppression, the use of antilymphocytethe availability of newer antiviral and antimicrobial
agents, and a better treatment of comorbidity. It is likely antibodies, sun exposure and viral infections can favor
the development of tumors in organ transplant recipi-that the use of newer immunosuppressive drugs also
contributed to a better graft survival, although no single ents. Measures to reduce the risk of tumor may include
low exposure to sun, avoidance of smoking, and low-regimen appeared to be statistically superior. The lack
of difference between monotherapy, dual therapy and dose immunosuppression whenever possible [27]. Regu-
lar surveillance is recommended in order to allow antriple therapy with CsA was somewhat expected, as a
recent multicenter trial showed a similar graft survival early diagnosis of malignancy.
Infection is becoming more rare as a cause of deathat 10 years in patients assigned to any of these three
regimens [17]. Because of the good graft survival the [12] and this was confirmed in this study. Progress in the
diagnosis and treatment of infections as well as improvednumber of patients assigned to mycophenolate mofetil
or sirolimus/everolimus was too small to detect any sig- methods of immunosuppression certainly contributed to
a consistent decline in the incidence of fatal infections.nificant difference. Of interest, in our patients, all of
whom were treated with CsA, the mean plasma creati- Liver failure was the fourth cause of death and mostly
occurred in HBV or HCV positive patients. HBV-posi-nine levels tended to remain stable over the time, con-
firming previous results showing that prolonged expo- tive renal transplant recipients may remain asymptom-
atic for years, but in the long-term they have an increasedsure to CsA does not necessarily lead to progressive graft
dysfunction [18, 19]. risk of death from liver cirrhosis and/or extrahepatic
sepsis [28]. The prognosis seems to be better for HCVDeath with a functioning graft was the second cause
of late failure in this series. As already pointed out by positive patients who have a life expectancy similar to
that of HCV negative patients [29]. Nevertheless, a num-the UNOS results [15], our experience showed cardiovas-
cular disease as the leading cause of death. Both pre- ber of patients may develop liver cirrhosis and die, usu-
ally after 10 or more years. We did not take particulartransplant and post-transplant variables influenced the
risk of cardiovascular events. In agreement with other measures in HCV positive patients. We excluded from
transplantation those patients with biopsy-proved chronicstudies we found that pre-transplant variables such as
previous cardiovascular events [20], age [20], arterial hy- active hepatitis and tried to reduce immunosuppression
when possible. Only three out of 126 HCV positive pa-pertension [20, 21] smoking [20, 22] and long-term dial-
ysis [8, 23] significantly increased the risk of de novo tients died from liver failure but two of them were also
HBV positive. Two other HCV positive patients died fromcardiovascular complications after transplantation.
Diabetes is another well-recognized risk factor for car- extra-hepatic infection, four from cardiovascular disease
and three from extra-hepatic neoplasia. These data con-diovascular disease, but since we transplanted very few
diabetic patients, it did not emerge as a significant risk firm that mortality is directly caused by liver failure only
in a minority of HCV positive patients [30]. Whateverfactor in our study. These data outline the importance of
careful selection and preparation of the recipient before the cause of death, it is clear that mortality with graft
functioning is a major limit for long-term graft survival.transplantation in order to prevent post-transplant car-
diovascular complications. This is outlined by the increase of graft half-life from 20
to 30 years, after censoring our data by death.After transplantation, the same variables plus hyper-
lipidemia increased the risk of cardiovascular complica- Recurrent glomerulonephritis was the third cause of
late failure. Previous studies pointed out that the grafttions. While age and duration of dialysis cannot be modi-
fied, these data emphasize that in transplant recipients, loss was more frequent in patients with recurrent renal
disease than in those without recurrence [31]. However,as well as in the general population, the lifestyle and the
type of diet can influence the development of cardiovas- little attention has been paid to whether patients with glo-
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